Company: EDSA
Filing Date: 2025-09-09
Form Type: 8-K
Source: 0001171843-25-005800
Chunk: 0

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On September 9, 2025,
Edesa Biotech, Inc. (the “ Company”), filed a prospectus supplement (the “ Prospectus Supplement”) with the
U. S. Securities and Exchange Commission (the “ SEC”) in connection with the Company’s “at the market
offering” program for the offer and sale of up to $4,006,544 of the Company’s common shares, without par value (the
“ Common Shares”), from time to time through H. C. Wainwright & Co., LLC (“ Wainwright”), as sales agent,
pursuant to the Company’s existing At the Market Offering Agreement (the “ ATM Agreement”), dated October 4, 2024.
As of the date hereof, the Company has sold an aggregate of $837,134 of Common Shares pursuant to the ATM Agreement and the related
prospectus supplement, dated October 4, 2024 to the Company’s Registration Statement on Form S-3 (333-266604).

The offer and sale of additional
Common Shares by the Company under the ATM Agreement will be made pursuant to the Prospectus Supplement, dated September 9, 2025, and
the accompanying base prospectus, dated September 9, 2025, contained therein, which together form a part of the Company’s shelf
registration statement on Form S-3 (File No. 333-288966), initially filed with the SEC on July 25, 2025 and declared effective by the
SEC on September 9, 2025 (the “ Registration Statement”).

Fasken Martineau DuMoulin
LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $4,006,544 Common Shares that may be offered and
sold pursuant to the ATM Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein,
is attached as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form
8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor shall there be
any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.